Welcome to our dedicated page for EyePoint SEC filings (Ticker: EYPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on EyePoint's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into EyePoint's regulatory disclosures and financial reporting.
EyePoint, Inc. reported that an independent Data Safety Monitoring Committee completed its third scheduled review of the pivotal Phase 3 DURAVYU™ program for wet age-related macular degeneration and recommended that the LUGANO and LUCIA trials continue as planned with no protocol changes.
As of May 2, 2026, all active patients in the treatment arm had reached the Week 32 visit and received a second DURAVYU dose, with over 35% receiving a third dose at Week 56. Interim masked safety data show a continued favorable safety profile, consistent with experience in over 190 patients across four completed trials. The identical, aflibercept-controlled Phase 3 studies have enrolled over 900 patients, with topline wet AMD data expected beginning in mid-2026, while separate Phase 3 trials in diabetic macular edema are underway with data anticipated in the second half of 2027.
EyePoint, Inc. files an amended Schedule 13G/A reporting that Adage Capital Management and affiliated reporting persons beneficially own 3,300,000 shares of Common Stock, representing 3.96% of the class. The percentage is calculated using 83,431,950 shares outstanding as of February 27, 2026 per the company's Form 10-K.
The amendment attributes shared voting and dispositive power over the 3,300,000 shares to Adage entities and to named individuals Robert Atchinson and Phillip Gross; signatures by the reporting persons appear on the filing.
EyePoint, Inc. reported first-quarter 2026 results, combining heavier investment in its DURAVYU retinal franchise with a larger loss. Total revenue was $0.7 million, down from $24.5 million a year earlier, mainly because prior-year results included recognition of deferred license revenue from YUTIQ rights.
Operating expenses rose to $87.9 million from $73.3 million, driven by Phase 3 DURAVYU trials in wet AMD and DME and scaling its commercial manufacturing facility. EyePoint posted a net loss of $84.8 million, or ($0.99) per share, versus a $45.2 million loss, or ($0.65) per share, in 2025.
Cash, cash equivalents and marketable securities totaled $223 million as of March 31, 2026, down from $306 million on December 31, 2025. The company expects this cash to fund operations into the fourth quarter of 2027, beyond anticipated DURAVYU Phase 3 wet AMD milestones beginning mid-2026.
EyePoint, Inc. outlines strong 2025 execution and asks stockholders to act on key governance items at its virtual 2026 annual meeting. The company highlights rapid enrollment of over 900 patients in two Phase 3 LUGANO and LUCIA trials of DURAVYU for wet age-related macular degeneration and positive Phase 2 VERONA data in diabetic macular edema, with Phase 3 DME trials COMO and CAPRI underway. DURAVYU, a vorolanib intravitreal insert using Durasert E bioerodible technology, has shown no safety signals across more than 190 treated patients and has FDA‑conditionally accepted branding, though it remains investigational. Stockholders as of April 21, 2026 will vote on electing eight directors, approving Amendment No. 3 to the 2023 Long-Term Incentive Plan to add 4,900,000 shares, an advisory say-on-pay resolution, and ratification of Deloitte & Touche as independent auditor.
EyePoint, Inc. Chief Medical Officer Ramiro Ribeiro exercised stock options and sold the resulting shares in a same-day transaction. On April 17, 2026, he exercised options to acquire 2,437 shares of common stock at $8.26 per share, then sold 2,437 shares at $15.00 per share in an open-market sale.
Following these transactions, he reported no common stock held directly, while 80,438 stock options remained outstanding with an expiration date in 2035.
EYPT related Form 144: reported planned sale of 9,750 shares and recent 10b5-1 dispositions. The filing states 9,750 shares of Common stock are to be sold on 04/17/2026 in connection with an exercise of stock options for cash. It also lists prior 10b5-1 sales by Ramiro Ribeiro of 2,438 shares on 03/04/2026 (proceeds $43,571.69) and 2,437 shares on 02/17/2026 (proceeds $36,555.00).
EyePoint, Inc. filed an 8-K to share an updated investor presentation focused on DURAVYU, its sustained-release tyrosine kinase inhibitor for retinal disease. The deck highlights Phase 3 programs in wet age-related macular degeneration and diabetic macular edema, with topline wet AMD data expected beginning in mid-2026.
EyePoint reports approximately $220 million in cash and investments as of March 31, 2026, which it believes supports its operating runway into the fourth quarter of 2027. Phase 3 wet AMD trials LUGANO and LUCIA are fully enrolled at roughly 400 patients each, while Phase 3 DME trials COMO and CAPRI target about 240 patients each with full enrollment anticipated in the third quarter of 2026. The company is also scaling a 41,000 square-foot commercial manufacturing facility in Northbridge, Massachusetts to support a potential New Drug Application filing and commercialization of DURAVYU.
The Vanguard Group filed an amendment on a Schedule 13G/A reporting zero shares beneficially owned of EyePoint Inc Common Stock and 0% of the class. The amendment states that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries and business divisions will report beneficial ownership separately and Vanguard no longer is deemed to beneficially own those securities. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
EyePoint, Inc. President and CEO Jay S. Duker restructured his holdings by selling shares and stock options to a family trust. On March 23, 2026, he sold 76,766 shares of Common Stock and options over an additional 150,000 shares to the Duker Family 2024 Irrevocable Trust in exchange for a promissory note of $2,398,220.93, reflecting the fair market value of the securities. After the transactions, he continued to hold some Common Stock and options directly, while the Family Trust held the transferred positions. The securities in the Family Trust are for the benefit of his children, his spouse serves as trustee, and he disclaims beneficial ownership of those trust-held securities.